The CIML (Inserm/CNRS/AMU) is proud to announce that Dr. Sandrine Roulland, Inserm Research Director and team leader at CIML, has been selected as a recipient of the prestigious Idea Award from the Institute for Follicular Lymphoma Innovation (IFLI).
This distinction, which is part of the Moonshot program launched in June 2023, recognizes scientific excellence and innovation in follicular lymphoma research. Dr. Roulland, in collaboration with Prof. Karin Tarte from the University of Rennes, has been selected for her innovative project titled "Hunting Cancer Precursor Cells (CPCs) at the Origin of Follicular Lymphoma Relapse."
CIML is particularly delighted by this recognition, which highlights the excellence of research conducted within our institute. Dr. Roulland's project, which will receive initial two-year funding with the possibility of extension, will significantly contribute to our understanding of follicular lymphoma development and progression mechanisms.
The IFLI Idea Award aims to deepen our understanding of follicular lymphoma by focusing on the role of precursor cells. Using cutting-edge technologies, this research will explore the molecular mechanisms and pathways that lead to disease development, paving the way for innovative treatments. https://tinyurl.com/4aa6pzym
